Growth Hormone Deficiency
Pipeline by Development Stage
Endocrinology is a $1.4B mature market dominated by legacy products and characterized by significant patent cliff exposure in the near-term.
Key Trends
- Two blockbusters (FORTEO, SYNTHROID) approaching LOE with $780M combined spend
- Growth phase products (ORGOVYX, TYMLOS) entering peak revenue years through 2040
- Heavy trial activity (625 total) concentrated in Phase 3 and Phase 4 studies indicating established disease focus
Career Verdict
Endocrinology offers stability and specialized expertise but limited growth upside; best suited for professionals comfortable in mature markets seeking deep disease knowledge rather than explosive market expansion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | FORTEO (TERIPARATIDE) | Eli Lilly and Company | $425M | 30% | LOE_APPROACHING | Declining | |
| 2 | SYNTHROID (LEVOTHYROXINE SODIUM) | AbbVie | $355M | 25% | LOE_APPROACHING | Declining | |
| 3 | ORGOVYX (RELUGOLIX) | Sumitomo Dainippon Pharma | $277M | 20% | PEAK | Stable | 11.4yr |
| 4 | TYMLOS (ABALOPARATIDE) | Radius Health | $198M | 14% | PEAK | Stable | 13.7yr |
Drug Class Breakdown
LOE approaching; potential for new mechanisms
Mature, multiple generics; limited differentiation
Growth trajectory through 2037
Stable; multiple biosimilars in market
Emerging niche for rare endocrine disorders
Career Outlook
StableEndocrinology offers deep specialization and stable employment but limited growth trajectory; market maturity and patent cliff exposure create restructuring risk for legacy product teams at large pharma. Career advancement depends on niche expertise (rare endocrine disorders, bone metabolism) and willingness to work at smaller or specialist biotech firms where hiring is concentrated. Compensation is moderate relative to other therapeutic areas, with Medical Affairs and Clinical Operations commanding premiums.
Breaking In
Prioritize roles at Neurocrine Biosciences or other specialist firms over large pharma to gain endocrinology depth; seek Clinical Operations or IT positions for better compensation and career stability.
For Experienced Professionals
Experienced professionals should pursue Medical Affairs or senior Clinical Operations roles (highest salaries) or consider pivoting to emerging indications (GnRH antagonists in non-prostate oncology, novel PTH mechanisms) to avoid legacy product decline.
In-Demand Skills
Best For
Hiring Landscape
Endocrinology hiring is concentrated at specialist biotech firms (Neurocrine: 126 jobs, 93% of available positions) rather than large pharma, indicating a niche market dynamic. IT roles dominate openings (51 jobs, $201K avg) followed by R&D (21 jobs, $120K avg), suggesting company-level digitalization and data infrastructure needs. Compensation ranges widely ($115K-$359K), with Medical Affairs offering premium salaries ($359K) but minimal openings (6 jobs).
By Department
Limited total opportunity (135 jobs) concentrated at one biotech firm signals a tight job market; IT and Clinical Operations offer best compensation, but specialized endocrinology roles are scarce.
On Market (5)
Approved therapies currently available
Competitive Landscape
21 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 9,337 patients across 50 trials
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
Study of TV-1106 in Growth Hormone-Deficient Adults
Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
A Study of Zomacton in Children With Growth Hormone Deficiency
Genotropin Study Assessing Use of Injection Pen
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency
Practicability and Acceptability of Stylomax® in Children
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
Skeletal Muscle Effects of GH in Boys
Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency
Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)
A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece
Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®
Related Jobs in Endocrinology
Vice President, Reproductive Medicine
Associate Director, Program Safety Lead - Job ID: 1908
Product Manager Endocrinology (f/m/d)
Talent Pool
Group Leader - Senior Director, Quantitative Pharmacology and Pharmacometrics (Hybrid or Remote)
Sr. Consultant, Data Analyst & Commercial Productivity
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.